MCRB Seres Therapeutics, Inc.

NASDAQ
$3.52

Seres Therapeutics, Inc. (MCRB) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $1.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -37.5% since its last earnings release on August 5, 2026.

Seres Therapeutics Beat Consensus Estimates
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($1.34)
Rev est $200K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.77

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.